Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Manzanita Pharmaceuticals General Information
Manzanita Pharmaceuticals has developed a proprietary platform that attaches near-infrared dyes or drugs to recombinant human neurotrophins such as NGF and BDNF. Their lead product, NerveLight, is an intra-operative nerve imaging agent designed to help surgeons visualize nerves during procedures like radical prostatectomy, aiming to reduce complications such as impotence or incontinence. The company also develops non-opiate glucocorticoid injectables for chronic pain. At least one pipeline program targeting optic neuritis with FA-rhBDNF is in preclinical development.[1][3][4][8]
Contact Information
Primary Industry
Biotech
Corporate Office
Woodside, California
United States
United States
Drug Pipeline
NerveLight
Pre-clinicalKey Partnerships
Manzanita Pharmaceuticals Funding
No funding data available
To view Manzanita Pharmaceuticals's complete valuation and funding history, request access »